FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:168-174 July 18, 2002 Number 3 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Liang, T. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes. HBeAg is thus a surrogate marker for the presence of hepatitis B virus DNA. We conducted a prospective study to determine the relation between positivity for hepatitis B surface antigen (HBsAg) and HBeAg and the development of hepatocellular carcinoma.

Methods In 1991 and 1992, we enrolled 11,893 men without evidence of hepatocellular carcinoma (age range, 30 to 65 years) from seven townships in Taiwan. Serum samples obtained at the time of enrollment were tested for HBsAg and HBeAg by radioimmunoassay. The diagnosis of hepatocellular carcinoma was ascertained through data linkage with the computerized National Cancer Registry in Taiwan and with death certificates. We performed a multiple regression analysis to determine the relative risk of hepatocellular carcinoma among men who were positive for HBsAg alone or for HBsAg and HBeAg, as compared with those who were negative for both.

Results There were 111 cases of newly diagnosed hepatocellular carcinoma during 92,359 person-years of follow-up. The incidence rate of hepatocellular carcinoma was 1169 cases per 100,000 person-years among men who were positive for both HBsAg and HBeAg, 324 per 100,000 person-years for those who were positive for HBsAg only, and 39 per 100,000 person-years for those who were negative for both. After adjustment for age, sex, the presence or absence of antibodies against hepatitis C virus, cigarette-smoking status, and use or nonuse of alcohol, the relative risk of hepatocellular carcinoma was 9.6 (95 percent confidence interval, 6.0 to 15.2) among men who were positive for HBsAg alone and 60.2 (95 percent confidence interval, 35.5 to 102.1) among those who were positive for both HBsAg and HBeAg, as compared with men who were negative for both.

Conclusions Positivity for HBeAg is associated with an increased risk of hepatocellular carcinoma.

Source Information

From the Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei (H.-I.Y., S.-L.Y., C.K.H., C.-J.C.); the Department of Gastroenterology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung (S.-N.L.); Chang-Gung Memorial Hospital and Chang-Gung University, Taoyuan (Y.-F.L.); the Department of Public Health, National Defense Medical Center, Taipei (C.-A.S.); the Graduate Institute of Aboriginal Health, Tzu Chi University, Hualien (L.-Y.W.); and the Liver Research Unit and Hepatitis Research Center, National Taiwan University Hospital (P.-J.C., D.-S.C.) — all in Taiwan.

Address reprint requests to Dr. Chien-Jen Chen at the College of Public Health, National Taiwan University, 1 Jen-Ai Rd., Section 1, Taipei 10018, Taiwan, or at cjchen{at}ha.mc.ntu.edu.tw.

Full Text of this Article

Related Letters:

Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Geier A., Gartung C., Dietrich C. G., Chen C.-J., Yang H.-I, You S.-L.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:1721-1722, Nov 21, 2002. Correspondence

This article has been cited by other articles:

• He, Y., Zhang, H., Yin, J., Xie, J., Tan, X., Liu, S., Zhang, Q., Li, C., Zhao, J., Wang, H., Cao, G. (2009). IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis 30: 1916-1922 [Abstract] [Full Text]  
• Liu, S., Zhang, H., Gu, C., Yin, J., He, Y., Xie, J., Cao, G. (2009). Associations Between Hepatitis B Virus Mutations and the Risk of Hepatocellular Carcinoma: A Meta-Analysis. JNCI J Natl Cancer Inst 101: 1066-1082 [Abstract] [Full Text]  
• Fwu, C.-W., Chien, Y.-C., Kirk, G. D., Nelson, K. E., You, S.-L., Kuo, H.-S., Feinleib, M., Chen, C.-J. (2009). Hepatitis B Virus Infection and Hepatocellular Carcinoma Among Parous Taiwanese Women: Nationwide Cohort Study. JNCI J Natl Cancer Inst 101: 1019-1027 [Abstract] [Full Text]  
• Chan, H. L.-Y., Wong, V. W.-S., Wong, G. L.-H., Chim, A. M.-L., Lai, L. H., Sung, J. J.-Y. (2009). Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. J. Clin. Microbiol. 47: 1830-1836 [Abstract] [Full Text]  
• Pai, A., Lin, A. (2008). Chronic Asymptomatic Hepatitis B Presenting With Metastatic Hepatocellular Carcinoma. JCO 26: 4209-4211 [Full Text]  
• Yin, J., Zhang, H., Li, C., Gao, C., He, Y., Zhai, Y., Zhang, P., Xu, L., Tan, X., Chen, J., Cheng, S., Schaefer, S., Cao, G. (2008). Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis 29: 1685-1691 [Abstract] [Full Text]  
• Yang, H.-I, Yeh, S.-H., Chen, P.-J., Iloeje, U. H., Jen, C.-L., Su, J., Wang, L.-Y., Lu, S.-N., You, S.-L., Chen, D.-S., Liaw, Y.-F., Chen, C.-J., For the REVEAL-HBV Study Group, (2008). Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma. JNCI J Natl Cancer Inst 100: 1134-1143 [Abstract] [Full Text]  
• Singh, N. A., Reau, N. (2008). Management of hepatitis B virus. J Antimicrob Chemother 62: 224-228 [Abstract] [Full Text]  
• Lu, S.-N., Wang, J.-H., Chen, P.-F., Tung, H.-D., Tseng, P.-L., Hung, C.-H., Kee, K.-M., Chen, C.-H., Chang, K.-C., Lee, C.-M., Changchien, C.-S., Chen, Y.-D., Tsai, L.-S., Chen, T. H.-H. (2008). Community-Based Mass Ultrasonographic Screening of Hepatocellular Carcinoma among Thrombocytopenic Adults. Cancer Epidemiol. Biomarkers Prev. 17: 1813-1821 [Abstract] [Full Text]  
• Sokal, E. M., Kelly, D., Wirth, S., Mizerski, J., Dhawan, A., Frederick, D. (2008). The Pharmacokinetics and Safety of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B Virus Infection. J Clin Pharmacol 48: 512-517 [Abstract] [Full Text]  
• Chan, H. L.-Y., Tse, C.-H., Mo, F., Koh, J., Wong, V. W.-S., Wong, G. L.-H., Lam Chan, S., Yeo, W., Sung, J. J.-Y., Mok, T. S.-K. (2008). High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. JCO 26: 177-182 [Abstract] [Full Text]  
• Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]  
• Tian, X., Zhao, C., Ren, J., Ma, Z.-M., Xie, Y.-H., Wen, Y.-M. (2007). Gene-expression profiles of a hepatitis B small surface antigen-secreting cell line reveal upregulation of lymphoid enhancer-binding factor 1. J. Gen. Virol. 88: 2966-2976 [Abstract] [Full Text]  
• Pungpapong, S., Kim, W. R., Poterucha, J. J. (2007). Natural History of Hepatitis B Virus Infection: An Update for Clinicians. Mayo Clin Proc. 82: 967-975 [Abstract] [Full Text]  
• Lai, C.-L., Yuen, M.-F. (2007). The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. ANN INTERN MED 147: 58-61 [Abstract] [Full Text]  
• Lim, C. Y., Kowdley, K. V. (2007). Optimal duration of therapy in HBV-related cirrhosis. J Antimicrob Chemother 60: 2-6 [Abstract] [Full Text]  
• Yang, C.-Y., Kuo, T.-H., Ting, L.-P. (2006). Human Hepatitis B Viral e Antigen Interacts with Cellular Interleukin-1 Receptor Accessory Protein and Triggers Interleukin-1 Response. J. Biol. Chem. 281: 34525-34536 [Abstract] [Full Text]  
• Kirk, G. D., Bah, E., Montesano, R. (2006). Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis 27: 2070-2082 [Abstract] [Full Text]  
• Chien, Y.-C., Jan, C.-F., Kuo, H.-S., Chen, C.-J. (2006). Nationwide Hepatitis B Vaccination Program in Taiwan: Effectiveness in the 20 Years After It Was Launched. Epidemiol Rev 28: 126-135 [Abstract] [Full Text]  
• Park, N H, Song, I H, Chung, Y-H (2006). Chronic hepatitis B in hepatocarcinogenesis.. Postgrad. Med. J. 82: 507-515 [Abstract] [Full Text]  
• Larson, A. M., Curtis, J. R. (2006). Integrating palliative care for liver transplant candidates: "too well for transplant, too sick for life".. JAMA 295: 2168-2176 [Abstract] [Full Text]  
• Huo, T-I, Wu, J-C, Lee, S-D, Yuen, M-F, Lai, C-L (2006). Do baseline ALT levels predict complications of chronic hepatitis B? * Authors' reply. Gut 55: 745-746 [Full Text]  
• Yuan, J.-M., Gao, Y.-T., Ong, C.-N., Ross, R. K., Yu, M. C. (2006). Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma.. JNCI J Natl Cancer Inst 98: 482-490 [Abstract] [Full Text]  
• Chen, C.-J., Yang, H.-I., Su, J., Jen, C.-L., You, S.-L., Lu, S.-N., Huang, G.-T., Iloeje, U. H., for the REVEAL-HBV Study Group, (2006). Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. JAMA 295: 65-73 [Abstract] [Full Text]  
• Yuen, M-F, Yuan, H-J, Wong, D K-H, Yuen, J C-H, Wong, W-M, Chan, A O-O, Wong, B C-Y, Lai, K-C, Lai, C-L (2005). Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54: 1610-1614 [Abstract] [Full Text]  
• Tanabe, K. K., Blaszkowsky, L. S., Chung, R. T., Blake, M. A., Lauwers, G. Y. (2005). Case 23-2005 - A 57-Year-Old Man with a Mass in the Liver. NEJM 353: 401-410 [Full Text]  
• Goedert, J. J. (2005). Preventing Infection-Associated Cancer: From Bench to Hillside. JNCI J Natl Cancer Inst 97: 245-246 [Full Text]  
• Yu, M.-W., Yeh, S.-H., Chen, P.-J., Liaw, Y.-F., Lin, C.-L., Liu, C.-J., Shih, W.-L., Kao, J.-H., Chen, D.-S., Chen, C.-J. (2005). Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. JNCI J Natl Cancer Inst 97: 265-272 [Abstract] [Full Text]  
• Chan, H. L.-Y., Leung, N. W.-Y., Hui, A. Y., Wong, V. W.-S., Liew, C.-T., Chim, A. M.-L., Chan, F. K.-L., Hung, L. C.-T., Lee, Y.-T., Tam, J. S.-L., Lam, C. W.-K., Sung, J. J.-Y. (2005). A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-{alpha}2b and Lamivudine with Lamivudine Alone. ANN INTERN MED 142: 240-250 [Abstract] [Full Text]  
• Thio, C. L., Mosbruger, T. L., Kaslow, R. A., Karp, C. L., Strathdee, S. A., Vlahov, D., O'Brien, S. J., Astemborski, J., Thomas, D. L. (2004). Cytotoxic T-Lymphocyte Antigen 4 Gene and Recovery from Hepatitis B Virus Infection. J. Virol. 78: 11258-11262 [Abstract] [Full Text]  
• Hann, H.-W. L., Lee, J., Bussard, A., Liu, C., Jin, Y. R., Guha, K., Clayton, M. M., Ardlie, K., Pellini, M. J., Feitelson, M. A. (2004). Preneoplastic Markers of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cancer Res. 64: 7329-7335 [Abstract] [Full Text]  
• Liaw, Y. F., Sung, J. J.Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., Dixon, J. S., Gray, D. F., Sabbat, J., the Cirrhosis Asian Lamivudine Multicentre Study G, (2004). Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. NEJM 351: 1521-1531 [Abstract] [Full Text]  
• Chan, H L-Y, Hui, A Y, Wong, M L, Tse, A M-L, Hung, L C-T, Wong, V W-S, Sung, J J-Y (2004). Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53: 1494-1498 [Abstract] [Full Text]  
• Jou, Y.-S., Lee, C.-S., Chang, Y.-H., Hsiao, C.-F., Chen, C.-F., Chao, C.-C., Wu, L. S.H., Yeh, S.-H., Chen, D.-S., Chen, P.-J. (2004). Clustering of Minimal Deleted Regions Reveals Distinct Genetic Pathways of Human Hepatocellular Carcinoma. Cancer Res. 64: 3030-3036 [Abstract] [Full Text]  
• Ganem, D., Prince, A. M. (2004). Hepatitis B Virus Infection -- Natural History and Clinical Consequences. NEJM 350: 1118-1129 [Full Text]  
• Sande, M. A., Ronald, A. R. (2004). Update in Infectious Diseases. ANN INTERN MED 140: 290-295 [Full Text]  
• Connor, F L, Rosenberg, A R, Kennedy, S E, Bohane, T D (2003). HBV associated nephrotic syndrome: resolution with oral lamivudine. Arch. Dis. Child. 88: 446-449 [Abstract] [Full Text]  
• Sun, C.-A., Wu, D.-M., Lin, C.-C., Lu, S.-N., You, S.-L., Wang, L.-Y., Wu, M.-H., Chen, C.-J. (2003). Incidence and Cofactors of Hepatitis C Virus-related Hepatocellular Carcinoma: A Prospective Study of 12,008 Men in Taiwan. Am J Epidemiol 157: 674-682 [Abstract] [Full Text]  
• Geier, A., Gartung, C., Dietrich, C. G., Chen, C.-J., Yang, H.-I, You, S.-L. (2002). Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. NEJM 347: 1721-1722 [Full Text]  
• (2002). Hepatitis B e Antigen Increases Risk for Hepatocellular Carcinoma. JWatch Infect. Diseases 2002: 7-7 [Full Text]  
• Liang, T. J., Ghany, M. (2002). Hepatitis B e Antigen -- The Dangerous Endgame of Hepatitis B. NEJM 347: 208-210 [Full Text]